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Background. Long-term consumption of Western diets can
lead to acquired syndrome X, which presents with obesity,
insulin resistance, hypertension, hyperlipidemia, and risk of
atherosclerotic cardiovascular disease. While plasma lipid ab-
normalities in syndrome X have been well characterized, their
molecular basis remains unclear. This study explored po-
tential mechanisms of hypercholesterolemia in diet-induced
syndrome X.
Methods. Female Fischer rats were fed a high-fat, refined-
carbohydrate (sucrose) diet (HFS) or standard rat chow (low-
fat, complex carbohydrate, LFCC) for 20 months. Plasma lipids
and hepatic tissue mRNA, protein, and/or activities of the key
enzymes and receptors involved in cholesterol metabolism were
determined.
Results. The HFS group exhibited hypertension, hyperlipi-
demia, insulin resistance, obesity, significant down-regulation
of hepatic cholesterol 7a-hydroxylase (the rate-limiting step
in cholesterol catabolism) and low-density lipoprotein (LDL)
receptor (LDL-R, the primary pathway of LDL clearance).
In contrast, hepatic tissue acyl-coenzyme A:cholesterol acyl-
transferase (ACAT-2, the primary enzyme involved in intra-
cellular esterification of cholesterol) and scavenger-receptor
class B, type 1 (SR-B1 or HDL receptor) were up-regulated.
While 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase mRNA expression was increased, its protein abun-
dance and activity were unchanged, and HMG-CoA reductase-
to-cholesterol 7a-hydroxylase ratio was increased in HFS-fed
animals.
Conclusion. Hypercholesterolemia in diet-induced syn-
drome X is associated with depressed cholesterol 7a-hydro-
xylase, diminished LDL-R, elevated ACAT, and increased
HMG-CoA reductase-to-cholesterol 7a-hydroxylase ratio.
These findings point to impaired hepatic catabolism and up-
take of cholesterol and inappropriate cholesterol production
capacity as the underlying causes of hypercholesterolemia in
rats with diet-induced syndrome X.
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The metabolic syndrome, also known as syndrome
X, refers to a constellation of abnormalities which
include insulin resistance, hypertension, endothelial
dysfunction, obesity, dyslipidemia, oxidative stress, in-
flammation, propensity for thromboembolism, and
arteriosclerotic cardiovascular disease [1–3]. The preva-
lence of the metabolic syndrome in westernized soci-
eties has risen at an alarming rate, affecting ∼23% of
the general population and ∼43% of those over 60 years
of age in the USA [4]. A sedentary lifestyle and un-
healthy diet (high saturated fat and refined carbohy-
drates) are largely responsible for the ever-increasing
occurrence of the metabolic syndrome and its com-
plications, namely type II diabetes and cardiovascular
disease. In fact, genetically normal rats fed a high-fat,
high-sucrose diet (HFS) for extended periods exhibit
nearly all features of the metabolic syndrome, pointing
to the central role of diet in the pathogenesis of this syn-
drome [5–9].
Dyslipidemia in syndrome X is marked by eleva-
tion of plasma triglycerides, small-dense LDL, as well
as a high total cholesterol to high-density lipoprotein
(HDL) ratio, denoting an atherogenic profile. In an
earlier study, we showed marked down-regulation of
skeletal muscle lipoprotein lipase and very-low-density
lipoprotein (VLDL) receptor in rats with diet-induced
syndrome X [10]. Acquired deficiencies of lipoprotein
lipase and VLDL receptor, which are the principal
pathways for clearance of triglyceride-rich lipoproteins
from the circulation, can, in part, account for the el-
evation of plasma triglyceride and VLDL in rats with
diet-induced metabolic syndrome. Moreover, the marked
down-regulation of lipoprotein lipase (LPL) and VLDL
receptor in the skeletal muscle, coupled with an eleva-
tion of adipose tissue LPL activity, points to a shift in
fatty acid metabolism from energy consumption in mus-
cle to energy storage in adipocytes. This phenomenon can
contribute to the development of obesity in rats with diet-
induced syndrome X despite the absence of hyperphagia
[10].
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We hypothesized that hypercholesterolemia associated
with long-term consumption of an HFS diet may reflect
altered hepatic expression of the key enzymes and re-
ceptors involved in cholesterol metabolism in rats with
diet-induced syndrome X. Accordingly, mRNA, protein
abundance, and/or enzymatic activities of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, the
rate-limiting enzyme in cholesterol biosynthesis, choles-
terol 7a-hydroxylase, the rate-controlling enzyme in
cholesterol catabolism to bile acids, low-density lipopro-
tein (LDL) receptor (LDL-R), the primary pathway of
LDL clearance from the plasma, scavenger-receptor class
B, type 1 (SR-B1), the main pathway of hepatic HDL
delipidation, and acyl-coenzyme A:cholesterol acyltrans-
ferase (ACAT-2), the primary enzyme responsible for in-
tracellular esterification of cholesterol, were determined
in the liver of rats after long-term HFS diet consumption.
The results were compared with those obtained in the
control rats fed standard rat chow (LFCC) diet.
METHODS
Animals and diets
All protocols were conducted in accordance with the
University of California, Los Angeles, Animal Research
Committee. Inbred female Fischer rats were obtained
from Harlan Sprague-Dawley, Inc. (San Diego, CA,
USA), at 2 months of age. We have used this rat model in
our previous studies, as the female Fischer rat normally
shows little weight gain beyond the maturation phase [9,
10]. The rats were randomly assigned to either the LFCC
or HFS diet. They were housed 4 per cage with a 12-
hour light cycle starting at 0700 hours at 75 to 76◦F, and
were fed ad libitum with bowls placed in the cages to
assure that all animals had access to the food. The di-
ets were prepared in powder form by Purina Test Di-
ets, Inc. (Purina, Richmond, IN, USA) and contained a
standard vitamin and mineral mix and all essential nu-
trients. The LFCC diet (Purina 5001) is low in saturated
fat and contains mostly complex carbohydrate (starch),
while the HFS diet is high in saturated and monounsat-
urated fat (primarily from lard plus a small amount of
corn oil) and high in refined-sugar (sucrose) as previously
described [7]. After 20 months, and an overnight fast to
eliminate any confounding effects of the last meal, the an-
imals were anesthetized with chloral hydrate (250 mg/kg
ip), the livers were harvested immediately, snap frozen in
liquid nitrogen, and stored at –70◦C until processed. In
addition, blood was collected from the inferior vena cava,
centrifuged for 10 minutes at 3000 rpm, and the plasma
was subsequently frozen in liquid nitrogen and stored at
−70◦C.
Plasma lipid levels
Total cholesterol was determined by an enzymatic
colorimetric assay using a kit supplied by Wako Di-
agnostics and Chemicals USA (Richmond, VA, USA).
Plasma HDL-cholesterol, LDL-cholesterol, and triglyc-
erides were determined using kits from Sigma Chemical
Company (St. Louis, MO, USA) [11]. The plasma lipid
concentrations from these animals have been previously
reported [10].
Hepatic cholesterol content
Total, free, and esterified cholesterol content were
quantified in hepatic tissue by Wako C and CII cholesterol
kits, as described earlier (Wako Diagnostics and Chemi-
cals,) [12].
Determination of LDL-R protein
Hepatic LDL-R protein abundance was determined in
the plasma membrane preparation by Western blot anal-
ysis using a mouse antibovine LDL-R antibody (Cortex
Biochem, Inc., Davis, CA, USA) as described previously
[13].
HMG-CoA reductase protein determination
HMG-CoA reductase protein abundance in the liver
extract was quantified by Western blot analysis as de-
scribed by Ness et al [14] using a polyclonal anti-
HMG-CoA reductase antibody (generously provided by
Professor G.C. Ness, Department of Biochemistry and
Molecular Biology, University of South Florida, Tampa,
Florida).
Determination of cholesterol 7a-hydroxylase protein
Cholesterol 7a-hydroxylase protein abundance in the
liver tissue preparation was determined by Western blot
analysis using a rabbit antirat cholesterol 7a-hydroxylase
antibody as described in our earlier studies [15]. The an-
tibody employed in this assay was generously provided
by Professor John Y.L. Chiang (Northeastern Ohio Uni-
versity College of Medicine, Rootstown, OH, USA).
Determination of ACAT-2 protein
Hepatic ACAT-2 protein abundance was quantified
by Western analysis using a polyclonal antibody against
ACAT-2 as described in our recent study [11]. The an-
tibody employed in these experiments was a generous
gift from Professor Lawrence L. Rudel, Department of
Biochemistry and Comparative Medicine, Wake Forest
University, Winston-Salem, North Carolina.
Determination of SR-B1 protein
Hepatic tissue HDL receptor abundance was deter-
mined in the liver tissue protein preparation by Western
blot using a polyclonal HDL receptor antibody (Novus
Biological, Inc., Littleton, CO, USA) and a horseradish
peroxidase–linked antirabbit immunoglobulin G (IgG)
(Amersham Life Science, Piscataway, NJ, USA) as de-
scribed in our earlier study [16].
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Table 1. Primers and probes used for the real time RT-PCR
GeneBank
Genes DNA sequence Accession No.
HMG-CoA Fa 5′-CATGCTGCCAACATCGTCA-3′
Reductase Rb 5′-CCCACATTCTGTGCTGCATC-3′ X55286
Pc 5′-6-FAM-TGCCATCTACATTGCATGTGCCCA-3′
Cholesterol Fa 5′-ACCTGCCGGTACTAGACAGCA-3′
7a Rb 5′-TGCGGATATTCAAGGATGCA-3′ NM 012942
Hydroxylase Pc 5′-6-FAM-CATCAAGGAGGCTCTGAGGCTTTCCA-3′
Fa 5′-CAACGGTGGCTGCCAGTAC-3′
LDL-R Rb 5′-GAACTTGGGTGAGTGGGCAC-3′ NM 175762
Pc 5′-6-FAM-TGTGCCTGCCTGCCCCTCAGAT-3′
Fa 5′-AGGGTGTTCGAAGGCATCC-3
SR-B1 Rb 5′-GACCCGTTGGCAAACAAAGT-3′ NM 031541
Pc 5′-6-FAM-ACTTATCGCTTCACGGCCCCCG-3′
Fa 5′-CTATACTGCCAGGAGTGGTACGC-3′
ACAT2 Rb 5′-AGCTCCCAAAATGTCGGCT-3′ AB075946
Pc 5′-6-FAM-CGGCGACACTGTCCCTTGCCC-3′
Fa 5′-ACATCCAAGGAAGGCAGCAG-3′
18s rRNA Rb 5′-TCGTCACTACCTCCCCGG-3′ X01117
Pc 5′-VIC-CGCGCAAATTACCCACTCCCGA-3′
a, Forward primer; b, reverse primer; c, probe.
Preparation of liver microsomes and activity assay
for ACAT and HMG-CoA reductase
Frozen liver (400 mg) was homogenized in ice-
cold buffer A containing 50 mmol/L Tris/HCl, pH 7.4,
250 mmol/L sucrose, 1 mmol/L EDTA, and protease in-
hibitors [1 mmol phenylmethylsulfonyl fluoride (PMSF),
10 lg/mL aprotinin, 5 lg/mL leupeptin, and 3 lg/mL
pepstatin]. Microsomes were then isolated by differential
centrifugation, resuspended in buffer A, divided into sev-
eral aliquots and stored at −70◦C until used. Microsomal
protein concentration was measured using the Bio-Rad
protein assay kit (Bio-Rad, Hercules, CA, USA). Hepatic
microsomal ACAT activity was quantified in a manner
which was identical to that described in our earlier stud-
ies [11]. Hepatic microsomal HMG-CoA reductase abun-
dance and activity were determined as described previ-
ously [17].
RNA preparation and real-time RT-PCR
Total RNA was prepared from frozen liver using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
RNeasy kit (Qiagen, Valencia, CA, USA) according to
the manufacturer’s procedures. RNA concentration was
determined by spectrophotometry. Quantitative real-
time reverse transcription-polymerase chain reaction
(RT-PCR) was performed with ABI 7700 real time PCR
thermocycler using a kit from Applied Biosystems (Fos-
ter City, CA, USA). One tenth lg of RNA was converted
to cDNA by reverse transcription in 5 lL of 5.5 mmol/L
MgCl2, 0.5 mmol/L of each dNTPs, 2.5 lmol/L of random
hexamer, 0.4 U of RNase inhibitor, and 1.25 U of reverse
transcriptase. The reaction mixture was incubated for re-
verse transcription for 10 minutes at room temperature
and subjected to one cycle consisting of 10 minutes at
25◦C, 30 minutes at 48◦C, and 5 minutes at 95◦C.
PCR was done using AmpliTaq DNA polymerase in
25 lL containing 5.5 mmol/L of MgCl2, 0.2 mmol/L
of each dATP, dCTP, and dGTP, 0.4 mmol/L of dUTP,
0.25 U of AmpliTaq DNA polymerase, 5 lL of re-
verse transcription mixture, and 0.2 lmol/L of 5′-
and 3′-primers, and 0.1 lmol/L of 6-FAM-conjugated
probe specific for HMG-CoA reductase, cholesterol 7a-
hydroxylase, LDL receptor, SR-B1, and ACAT-2. VIC-
conjugated probe and primers specific for 18s rRNA were
used as internal control. The primer sequences are sum-
marized in Table 1. PCR amplification was done for 45
cycles in two-step cycling of denaturation at 94◦C for
15 seconds, and annealing/extension at 60◦C for 1 minute.
The amplification process was analyzed and visualized
using the Applied Biosystems Sequence Detector soft-
ware (Applied Biosystems). The cycle number in the
logarithmic phase (Ct value) was used to assess relative
mRNA abundance in hepatic tissue of the study animals.
Mean normalized gene expression was calculated using
18s rRNA expression as a reference [18].
Statistical analysis
Data were analyzed using Student t test. Values are re-
ported as mean ± SE with 6 rats per group unless other-
wise indicated. Differences were considered statistically
significant at P < 0.05.
RESULTS
General data
Data are summarized in Table 2. Compared to
the LFCC group, the HFS group exhibited a 3.5-fold
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Table 2. Body weight, systolic blood pressure, plasma total
cholesterol (TC), LDL-C, VLDL-C, triglyceride (TG), TC-to-HDL-C
ratio, and hepatic tissue TC and esterified cholesterol in rats given
high-fat, high refined sugar (HFS) or low-fat, complex carbohydrate
(LFCC) diets for 20 months
LFCC HFS
Body weight g 260 ± 6 374 ± 9a
Systolic blood pressure mm Hg 123 ± 4 147 ± 4a
TC mmol/L 1.49 ± 0.10 5.56 ± 0.58a
LDL-C mmol/L 0.89 ± 0.06 3.45 ± 0.40a
VLDL-C mmol/L 0.37 ± 0.07 1.53 ± 0.23a
TG mmol/L 0.39 ± 0.04 2.58 ± 0.31a
TC/HDL-C ratio 4.15 ± 0.30 5.30 ± 0.42c
Liver TC mg/g 21.63 ± 0.89 27.13 ± 1.35b
Liver esterified cholesterol mg/g 18.1 ± 0.80 21.98 ± 1.45b
Values are mean and SE, N = 6 to 8 per group.
aP < 0.001; bP < 0.01; cP < 0.05.
elevation of serum total cholesterol and a 6.5-fold rise
in serum triglyceride concentration. This was coupled
with a nearly 4-fold increase in serum LDL-cholesterol
and VLDL-cholesterol concentrations, and a 50% rise in
LDL/HDL cholesterol ratio in the HFS compared with
the LFCC group.
Free and esterified cholesterol concentrations in the
liver tissue were modestly elevated, and serum-to-liver
cholesterol concentration ratio was 3.5-fold higher in the
HFS animals compared to those in the LFCC group. Like-
wise, body weight was higher in the HFS than in the LFCC
group.
HMG-CoA reductase and cholesterol 7a-hydroxylase
Data are illustrated in Figures 1 and 2. HMG-CoA
reductase mRNA abundance in the liver tissue of the
HFS group was significantly higher than that in the LFCC
group (P < 0.05). However, HMG-CoA reductase pro-
tein abundance and enzymatic activity were unchanged
in the HFS group. Despite severe hypercholesterolemia,
hepatic tissue cholesterol 7a-hydroxylase mRNA and
protein abundance were significantly lower in the HFS
group than in the LFCC group (P < 0.01). Consequently,
the HMG-CoA reductase-to-cholesterol 7a-hydroxylase
ratio, which reflects the balance between cholesterol syn-
thetic and cholesterol catabolic capacities, was markedly
increased in the HFS group.
LDL-R and SR-B1
Data are shown in Figures 3 and 4. Hepatic LDL-R
protein abundance in the HFS group was significantly re-
duced compared to that in the LFCC group (P < 0.001).
Although the mean value for hepatic LDL-R mRNA
abundance in the HFS group was lower than that in
the LFCC group, the difference did not reach statisti-
cal significance. In contrast to the LDL-R, hepatic SR-
B1 protein abundance was significantly increased (P <
0.005), and SR-B1 mRNA abundance was insignificantly
increased in the HFS group.
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Fig. 1. Representative Western blot and group data depicting HMG-
CoA reductase protein abundance, mRNA abundance, and enzymatic
activities in liver of rats fed the low-fat, complex carbohydrate (LFCC)
or high-fat, sucrose (HFS) diets. N = 6 per group. ∗P < 0.05.
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Fig. 2. Representative Western blot and group data depicting choles-
terol 7a-hydroxylase protein and mRNA abundance in liver of rats fed
the low-fat, complex carbohydrate (LFCC) or high-fat, sucrose (HFS)
diets. N = 6 per group. ∗P < 0.01.
ACAT-2
Data are depicted in Figure 5. Hepatic ACAT-2 pro-
tein abundance and ACAT activity were significantly el-
evated (P < 0.01), while ACAT-2 mRNA abundance was
insignificantly increased in the HFS group compared to
the LFCC group.
DISCUSSION
Hyperlipidemia is a major feature of the metabolic
syndrome, and one of the cardinal risk factors for coro-
nary artery disease. We have previously shown marked
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Fig. 3. Representative Western blot and group data depicting LDL-
receptor (LDL-R) protein and mRNA abundance in liver of rats fed
the low-fat, complex carbohydrate (LFCC) or high-fat, sucrose (HFS).
N = 6 per group. ∗P < 0.01.
hyperlipidemia, dysregulation of lipoprotein lipase and
VLDL receptor deficiency in this model of diet-induced
syndrome X [9]. The latter abnormalities could, in part,
account for the associated hypertriglyceridemia and im-
paired clearance of VLDL and chylomicrons in diet-
induced syndrome X. The present study was designed
to investigate the effect of diet-induced syndrome X on
protein expression of the key enzymes and receptors in-
volved in hepatic cholesterol metabolism.
HMG-CoA reductase is an endoplasmic reticulum–
bound and peroxisomal enzyme that is the rate-limiting
step in cholesterol biosynthesis. While this enzyme is ex-
pressed in all tissues, it is more abundantly expressed
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Fig. 4. Representative Western blot and group data depicting SR-B1
protein and mRNA abundance in liver of rats fed the low-fat, complex
carbohydrate (LFCC) or high-fat, sucrose (HFS). N = 6 per group.
∗P < 0.01.
in the liver, which plays a central role in regulation of
cholesterol metabolism and plasma cholesterol concen-
tration [19]. In addition to its critical role in production,
packaging, and secretion of cholesterol in the apopro-
tein B-containing lipoproteins, the liver is responsible for
cholesterol catabolism to bile acids for disposal in the
gut. The rate-limiting enzyme in cholesterol catabolism to
bile acids is the unique cytochrome P450 enzyme, choles-
terol 7a-hydroxylase [20]. Thus, the balance between
cholesterol biosynthesis and cholesterol catabolism by
the liver is a critical determinant of serum cholesterol con-
centration. Despite severe hypercholesterolemia, hepatic
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Fig. 5. Representative Western blot and group data depicting ACAT-2
protein and mRNA abundance, and ACAT activity in liver of rats fed
the low-fat, complex carbohydrate (LFCC) or high-fat, sucrose (HFS).
N = 6 per group. ∗P < 0.01.
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HMG-CoA reductase protein abundance and activity
were unchanged, and hepatic cholesterol 7a-hydroxylase
abundance was markedly reduced in HFS-fed animals.
Thus, severe hypercholesterolemia in diet-induced syn-
drome X was associated with a more than two-fold rise in
relative ratio of HMG-CoA reducatse-to-cholesterol 7a-
hydroxylase. This observation points to relative reduction
of cholesterol catabolism as a culprit in the pathogene-
sis of hypercholesterolemia in chronic, diet-induced syn-
drome X. It should be noted that in contrast to the high-
fat sugar diet employed here, consumption of high-fat,
high-cholesterol diets has been shown to down-regulate
hepatic HMG-CoA reductase [21, 22]. These observa-
tions point to the role of excess exogenous cholesterol
as a cause of down-regulation of hepatic HMG-CoA re-
ductase in the latter studies. As with the present study,
Vergara-Jimenez et al [23] reported no change in HMG-
CoA reductase in male guinea pigs fed a high-fat, su-
crose diet for 4 weeks. However, they found increased
cholesterol 7a-hydroxylase expression with short-term
consumption of HFS diet in guinea pigs. The difference
in cholesterol 7a-hydroxylase expression with HFS diet
between the present study and that found in the latter
study may be due to differences in duration of interven-
tion (4 weeks vs. 20 months), gender (males vs. females),
and species used (guinea pig vs. rat). It is of note that di-
ets high in either saturated or monounsaturated fat have
been shown to mitigate up-regulation of cholesterol 7a-
hydroxylase mRNA abundance and activity in response
to a high-cholesterol diet [24].
Plasma LDL concentration is a function of the rates
of LDL synthesis and catabolism. HFS-fed animals ex-
hibited a marked elevation of plasma LDL-cholesterol
concentration. The primary pathway of cholesterol clear-
ance by the liver is LDL-receptor–mediated uptake
of cholesterol-rich LDL particles [25–27]. Elevation of
serum total cholesterol and LDL-cholesterol in our HFS-
fed group was associated with marked down-regulation of
LDL-R protein expression. Liu et al [28] showed that con-
sumption of a high-fat, high-cholesterol diet decreases
hepatic LDL-receptor mRNA in mice. The reduction in
LDL-receptor noted here is not due to increased choles-
terol intake because the dietary cholesterol was normal
in our HFS group [7]. However, the shared characteris-
tic between the 2 diets was high-fat content, which must
be, in part, responsible for the LDL-receptor deficiency
found with both diets. In fact, studies by Srivastava et al
[29] support this contention, as diets high in fat or fat and
cholesterol depressed hepatic LDL-receptor mRNA in
mice. Additionally, Hara et al [30], utilizing 125I-labeled
LDL, demonstrated that substituting saturated fat with
complex carbohydrate increased the LDL binding to
LDL-receptor and lowered plasma LDL-cholesterol. The
biological significance of the LDL-receptor in cholesterol
metabolism is illustrated by hereditary LDL-receptor
deficiency, which leads to severe hypercholesterolemia
and premature atherosclerotic cardiovascular disease [31,
32]. Thus, because LDL-receptor protein content corre-
lates well with LDL-receptor activity [33], acquired LDL-
receptor deficiency in rats employed in the present study
can contribute to elevations of serum total cholesterol
and LDL-cholesterol concentrations in this model.
We have recently found significant down-regulation of
VLDL-receptor in both skeletal muscle and adipose tis-
sue, and marked reductions of lipoprotein lipase in the
skeletal muscle of rats with diet-induced syndrome X
[7]. Accordingly, the observed down-regulation of the
VLDL-receptor and lipoprotein lipase is expected to con-
tribute to the elevation of plasma VLDL in this model.
We have further shown that chronic HFS feeding induces
marked insulin resistance [7]. Insulin normally suppresses
VLDL secretion [34], and insulin resistance is associated
with the inability of insulin to suppress hepatic VLDL se-
cretion [35, 36]. These events work in concert to increase
the available pool of VLDL for eventual conversion to
LDL.
In contrast to LDL, in which the receptor-mediated
metabolism is well characterized, the precise regulation
of HDL metabolism is not entirely understood. HDL me-
diates the removal of surplus cholesterol from extrahep-
atic tissues and its disposal in the liver, commonly referred
to as “reverse cholesterol transport.” Acton et al [37, 38]
isolated and cloned a cell membrane-associated protein
that exhibited high-binding affinity for HDL. The au-
thors identified this protein as a scavenger receptor class
B, type 1 (SR-B1) molecule. Based on its high-binding
affinity for HDL, SR-B1 was identified as an HDL re-
ceptor [39]. Transient HDL binding to its hepatic recep-
tors results in removal and internalization of cholesterol
esters from HDL-2 particles without degradation or up-
take of the HDL apoprotein constituents [37, 38]. Hep-
atic SR-B1 abundance was increased in our rats with
diet-induced syndrome X. The elevation of SR-B1 pro-
tein abundance in HFS-fed animals indicates that HDL-
mediated hepatic cholesterol uptake may be relatively
intact, contrasting severe reduction of LDL-receptor in
this model. It would appear that an increase in SR-B1
activity would be desirable, since this may enhance the
delivery of HDL cholesterol esters to the liver. The avail-
able data on the regulation of SR-B1 expression are
limited. Spady et al [40] demonstrated that polyunsat-
urated fat increases SR-B1 expression, which may ac-
count for the HDL-reducing property of polyunsaturated
fat diets. Hepatic over-expression of SR-B1 dramatically
lowers plasma HDL and suppresses the development of
atherosclerotic lesions in mice [41]. Interestingly, SR-B1
can avidly bind oxidized lipids [42], which are elevated
in this model [8]. Consequently, the up-regulation of this
scavenger receptor may be a compensatory response for
the increase in oxidized lipids.
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Liver ACAT-2 protein abundance and ACAT enzy-
matic activity were markedly elevated in rats fed the
HFS diet. ACAT is an endoplasmic reticulum–bound
enzyme that catalyzes intracellular esterification of
cholesterol and formation of cholesterol ester in nearly
all mammalian cells. Two isotypes of ACAT have been
identified: ACAT-1, which is expressed in most tissues
[43], and ACAT-2, which is primarily expressed in the
liver and intestine [44–46]. Esterification of cholesterol
by ACAT limits its solubility in the cell membrane lipids
and promotes accumulation of cholesterol ester in the
fat droplets within the cytoplasm. Thus, normal ACAT
activity prevents potentially toxic accumulation of free
cholesterol in various cell membranes. In addition, by
modulating intracellular free cholesterol concentration,
ACAT plays an important role in regulation of the cellular
cholesterol signaling pathways [47]. Moreover, ACAT-
mediated esterification of cholesterol plays an important
role in packaging, production, and secretion of VLDL by
the liver [48–50]. Similarly, by lowering the free choles-
terol that regulates cholesterol 7a-hydroxylase, ACAT
modulates hepatic cholesterol catabolism [51], and thus,
plasma cholesterol concentration. Thus, up-regulation of
hepatic ACAT-2 abundance in the HFS-fed group can
contribute to the observed elevation of serum VLDL
concentration in this model. Hepatic esterified choles-
terol content was increased in our HFS-fed animals, thus
providing functional evidence for the observed increase
in ACAT activity. Moreover, inhibition of ACAT has
been shown to increase bile acid synthesis and choles-
terol 7a-hydroxylase expression [51]. Thus, up-regulation
of hepatic ACAT may have contributed to the reduction
of cholesterol 7a-hydroxylase, and hence, hypercholes-
terolemia in this model.
It is of note that the magnitude of the changes in pro-
tein abundance or activities of some of the measured
molecules did not match the changes seen in the cor-
responding mRNA abundance. This phenomenon illus-
trates the fact that the given proteins are separately regu-
lated at multiple levels and are subject to transcriptional,
translational, and post-translational regulation.
CONCLUSION
Severe dyslipidemia in rats with chronic, diet-induced
syndrome X is associated with marked down-regulations
of hepatic cholesterol 7a-hydroxylase and LDL-receptor,
coupled with marked up-regulation of hepatic ACAT
and elevated HMG-CoA reductase-to-cholesterol 7a-
hydroxylase ratio. Dysregulation of these important lipid
regulatory proteins, together with the previously demon-
strated down-regulations of lipoprotein lipase and VLDL
receptor, contributes to altered lipid metabolism in diet-
induced syndrome X.
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